IL-12家族与自身免疫性甲状腺疾病-现代医学

IL-12家族与自身免疫性甲状腺疾病

单位：哈尔滨医科大学附属第一医院内分泌科, 黑龙江哈尔滨 150001

分类号：R581.9

出版年·卷·期（页码）：2017·36·第八期（1171-1175）

摘要：

IL-12细胞因子家族成员包括IL-12，IL-23，IL-27和IL-35。上述家族成员具有相似的异质二聚体亚基结构，但它们的生物学功能截然不同，IL-12和IL-23是Th1、Th17促炎反应的增强剂，IL-27具有促炎和抑炎双向调节作用，而IL-35是重要的抑炎细胞因子。IL-12家族是近年来炎症和免疫学研究中一个较新且重要的标志，作为调节因子和标志物，它们与多种自身免疫性疾病的发生和发展密切相关。但IL-12家族与自身免疫性甲状腺疾病（AITD）关系的研究至今报道较少，本文拟就这方面的进展作一综述。

The IL-12 family members are consisted of IL-12, IL-23, IL-27, and IL-35.The above family members have similar heterodimeric structures, but their biological characteristics are very diverse, IL-12 and IL-23 are pro-inflammatory activators of Th1 and Th17 responses, IL-27 is bidirectional for inflammation, while IL-35 is a vital inhibitory cytokine. IL-12 family is an important inflammatory and immunological playmaker in recent years, as regulators and playmakers, they are closely associated with the occurrence and the development of many autoimmune diseases. But studies on the relationship between IL-12 family and autoimmune thyroid disease(AITD)reported so far are not many, this article summarizes the progresses on this topic.

参考文献：

[1] BEHZADI P,BEHZADI E,RANJBAR R. IL-12 Family cytokines:general characteristics,pathogenic microorganisms,receptors,and signalling pathways[J].Acta Microbiol Immunol Hung,2016,63(1):1-25.
[2] VIGNALI D A,KUCHROO V K.IL-12 family cytokines:immunological playmakers[J].Nat Immunol,2012,13(8):722-728.
[3] TRINCHIERI G.Interleukin-12 and the regulation of innate resistance and adaptive immunity[J].Nat Rev Immunol,2003,3(2):133-146.
[4] COLLISON L W,DELGOFFE G M,GUY C S,et al.The composition and signaling of the IL-35 receptor are unconventional[J].Nat Immunol,2012,13(3):290-299.
[5] LASEK W,ZAGOZDZON R,JAKOBISIAK M.Interleukin 12:still a promising candidate for tumor immunotherapy?[J].Cancer Immunol Immunother,2014,63(5):419-435.
[6] HAMZA T,BARNETT J B,LI B.Interleukin 12 a key immunoregulatory cytokine in infection applications[J].Int J Mol Sci,2010,11(3):789-806.
[7] VILLARINO A V,KANNO Y,FERDINAND J R,et al.Mechanisms of Jak/STAT signaling in immunity and disease[J].J Immunol,2015,194(1):21-27.
[8] OPPMANN B,LESLEY R,BLOM B,et al.Novel p19 protein engages IL-12p40 to form a cytokine,IL-23,with biological activities similar as well as distinct from IL-12[J].Immunity,2000,13(5):715-725.
[9] XU M,MIZOGUCHI I,MORISHIMA N,et al.Regulation of antitumor immune responses by the IL-12 family cytokines,IL-12,IL-23,and IL-27[J].Clin Dev Immunol,2010,2010(6):1203-1217.
[10] GAFFEN S L,JAIN R,GARG A V,et al.The IL-23-IL-17 immune axis:from mechanisms to therapeutic testing[J].Nat Rev Immunol,2014,14(9):585-600.
[11] O'SHEA J J,PLENGE R.JAK and STAT signaling molecules in immunoregulation and immune-mediated disease[J].Immunity,2012,36(4):542-550.
[12] ABDALLA A E,LI Q,XIE L,et al.Biology of IL-27 and its role in the host immunity against mycobacterium tuberculosis[J].Int J Biol Sci,2015,11(2):168.
[13] GUZZO C,MAT NFC,GEE K.Interleukin-27 induces a STAT1/3-and NF-κBdependent proinflammatory cytokine profile in human monocytes[J].J Biol Chem,2010,285(32):24404-24411.
[14] SUN L,HE C,NAIR L,et al.Interleukin 12(IL-12)family cytokines:role in immune pathogenesis and treatment of CNS autoimmune disease[J].Cytokine,2015,75(2):249-255.
[15] ITOH M,UCHIMURA K,YAMAMOTO K,et al.Distinctive response of thyroid-infiltrating mononuclear cells to B cell activation through CD40 and interleukin-4 in Graves' disease[J].Cytokine,2002,19(3):107-114.
[16] NAGAYAMA Y,MIZUGUCHI H,HAYAKAWA T,et al.Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4,a Th2 cytokine[J].J Immunol,2003,170(7):3522-3527.
[17] CHEN K,WEI Y,SHARP G C,et al.Induction of experimental autoimmune thyroiditis in IL-12-/-mice[J].J Immunol,2001,167(3):1720-1727.
[18] 袁莉,张卫东,胡佳,等.血清IL-10和IL-12在自身免疫性甲状腺疾病中的表达特征[J].中国临床医学,2003,10(1):13-15.
[19] 张进安,张健,徐利,等.自身免疫甲状腺病患者血清中IL-12和IL-18水平的分析[J].细胞与分子免疫学杂志,2006,22(5):630-632.
[20] TAMARU M,MATSUURA B,ONJI M.Increased levels of serum interleukin-12 in Graves' disease[J].Eur J Endocrinol,1999,141(2):111-6.
[21] MURAKAMI S,OKUBO K,TSUJI Y,et al.Serum levels of interleukin-12 in Graves' Disease and their dynamic changes after surgery[J].Surg Today,2005,35(12):1016-1020.
[22] YANAGIDA T,KATO T,IGARASHI O,et al.Second signal activity of IL-12 on the proliferation and Il-2R expression of T helper cell-1 clone[J].J Immunol,1994,152(10):919-28.
[23] TABARKIEWICZ J,POGODA K,KARCZMARCZYK A,etal.The role of IL-17 and Th17 lymphocytes in autoimmune diseases[J].Arch Immunol Ther Exp(Warsz),2015,63(6):435-449.
[24] KIKODZE N,PANTSULAIA I,CHIKOVANI T.The role of T regulatory and Th17 cells in the pathogenesis of rheumatoid arthritis(REVIEW)[J].Georgian Med News,2016,(261):62-68.
[25] ALVARENGA-FILHO H,SALLES M,HYGINO J,et al.Fatigue favors in vitro Th1 and Th17-like cell expansion and reduces corticoid sensitivity in MS patients[J].J Neuroimmunol,2017,303:81-89.
[26] NANBA T,WATANABE M,INOUE N,et al.Increases of the Th1/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease[J].Thyroid,2009,19(5):495-501.
[27] FIGUEROA-VEGA N,ALFONSO-PEREZ M,BENEDICTO I,et al.Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis[J].J Clin Endocrinol Metab,2010,95(2):953-962.
[28] RUGGERI R M,SAITTA S,CRISTANI M,et al.Serum interleukin-23(IL-23)is increased in Hashimoto's thyroiditis[J].Endocrine J,2014,61(4):359-363.
[29] 柳迎昭,彭辉勇,王丽,等.桥本甲状腺炎患者外周血IL-23水平及意义[J].江苏大学学报:医学版,2015,25(4):331-334.
[30] 姚秋明,王媛,周娇珍,等.IL-27在Graves病患者外周血中的表达[J].现代免疫学,2015,35(4):299-303.
[31] BOSSOWSKI A,MONIUSAKO M,DABROWSKA M,et al.Lower proportions of CD4+CD25(high)and CD4+FoxP3,but not CD4+CD25+CD127(low)FoxP3+T cell levels in children with autoimmune thyroid diseases[J].Autoimmunity,2013,46(3):222-230.
[32] 黄崇标,田野,崔焱,等.白细胞介素35的在肿瘤发展中的作用[J].中国肺癌杂志,2016,19(4):230-235.
[33] GUAN S Y,LENG R X,KHAN M I,etal.Interleukin-35:a potential therapeutic agent for autoimmune diseases[J].Inflammation,2017,40(1):303-310.
[34] YILMAZ H,CAKMAK M,CEYDILEK B,et al.Role of interlekin-35 as a biomarker in patients with newly diagnosed Hashimoto's thyroiditis[J].Endocr Regul,2016,50(2):55-61.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录